Drug Approval | October 26, 2021
Glenmark launches novel fixed-dose combination for diabetes
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
It is the first company to launch Remogliflozin, Vildagliptin and Metformin combination
_256_384.jpg)
The two doses of Covaxin are likely to be administered to children with a gap of 28 days
The company has already received the emergency use authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D to be administered in three doses on August 20
It is a recombinant nanoparticle protein-based vaccine
The Lancet study said that Sputnik Light showed 78.6 to 83.7 per cent efficacy against Covid-19, significantly higher than most two-shot vaccines
The panel is headed by DCGI Dr VG Somani with representatives from various state drug regulators and health ministry
Hetero’s drug is a biosimilar version of Roche’s Actemra/RoActemra and will be available at the end of this month
The bioequivalence study was conducted by Accutest Research India, one of the preferred CRO players in India
The trial will be conducted across eight sites in Maharashtra
The trial will be conducted across 10 sites in India
Subscribe To Our Newsletter & Stay Updated
